FDA Declines Emergency Use Authorization for ZYESAMI® (aviptadil) for subgroup of Patients with Critical COVID-19 at immediate risk of death from respiratory failure despite treatment with approved therapy, including remdesivir

Focus is now on NRX-101 for Bipolar Depression with Suicidality RADNOR, Pa., July 1, 2022 /PRNewswire/ — NRx Pharmaceuticals, Inc. (Nasdaq: NRXP), (“NRx Pharmaceuticals”), a clinical-stage biopharmaceutical company, today announced that the US Food and Drug Administration (FDA) has…

Click here to view original post